Elizabeth Holmes became one of the most talked-about entrepreneurs in America by promising that a tiny drop of blood could replace the traditional needle-and-vial blood draw. As the founder and CEO of Theranos, she claimed her company's machines could run dozens — and eventually hundreds — of diagnostic tests from a single finger prick, quickly and cheaply. That story made Holmes the youngest self-made female billionaire in the United States on paper, and it attracted a board packed with former secretaries of state. It also turned out to be false, leading to her fraud conviction and an 11-and-a-quarter-year prison sentence. Interest in Elizabeth Holmes has surged again in 2026 thanks to "You Can See Everything," a new A24 documentary directed by Nathan Fielder and Lance Oppenheim that followed Holmes and her partner Billy Evans in the 34 days before she reported to prison. Here is how Theranos's blood-testing technology was actually supposed to work — and why it never did.
The Promise: Hundreds of Tests From a Single Drop of Blood
Holmes founded the company that became Theranos in 2003, when she was just 19 years old. She has said a fear of needles motivated her: she wanted to run blood tests using only a tiny amount of blood taken from the tip of a finger, rather than the vials typically drawn from a vein in the arm. The pitch was simple and powerful — a patient would receive a small finger prick, the blood would be collected in a miniature tube, and a compact machine would analyze it on the spot.
Theranos gave its two key components memorable names. The blood-collection vessel was called the "nanotainer," a tube just 12.9 millimeters (0.51 inches) tall that held only a couple of drops of blood. The analysis machine was called the "Edison," reportedly named after inventor Thomas Edison. Later, in 2016, the company introduced a newer version it called the "miniLab."
How the Edison Device Was Supposed to Work
According to Theranos patents and marketing materials, the Edison was a point-of-care system that could communicate over the internet to receive instructions about which tests to run on a sample, and then send the results back. The machine was designed to compare results against medical data available online and, if needed, run more targeted follow-up tests. The idea was that a small desktop device could do the work of an entire clinical laboratory.
Even Theranos's own patent was vague about how much blood the Edison actually required. In one section, the patent described a sample of about 10 drops of blood; in another, it claimed the machine would need less than one drop. That inconsistency was an early warning sign, because the amount of blood available is one of the most important limits on what a blood test can reliably measure.
Why a Single Drop of Blood Was Never Enough
Medical experts were skeptical from the beginning. When Holmes first pitched the idea as a Stanford student, medicine professor Phyllis Gardner told her, "I don't think your idea is going to work," explaining that it was impossible to do what Holmes was claiming. Other expert professors told her the same thing.
The core problem is dilution. A finger-prick sample draws blood from tiny capillaries, and it mixes with fluid from surrounding tissue. That means the concentration of any given substance in a finger-prick drop can be less reliable than in a full venous draw. Running many different tests — which require different chemical reagents, calibrations, and volumes — from one or two drops is even harder, because there simply is not enough sample to split across dozens of separate reactions and still produce accurate results.
Theranos also never published peer-reviewed research. In February 2015, Stanford professor John Ioannidis wrote in the Journal of the American Medical Association that no peer-reviewed research from Theranos had appeared in medical literature. Months later, University of Toronto professor Eleftherios Diamandis analyzed the technology and concluded that "most of the company's claims are exaggerated."
The Reality: Third-Party Machines and Voided Results
The truth came out in October 2015, when Wall Street Journal reporter John Carreyrou published an investigation revealing that Theranos was running most of its tests on commercially available machines made by other companies — not on the Edison devices it had marketed. The report also said the Edison machines themselves might provide inaccurate results.
Whistleblowers such as Tyler Shultz, a former Theranos employee and the grandson of board member George Shultz, were key sources for the story. The company fought back, denying the allegations and sending lawyers after sources, but regulators soon piled on. In January 2016, the Centers for Medicare and Medicaid Services found that a Theranos lab posed "immediate jeopardy to patient health and safety" over a test used to dose the blood-thinning drug warfarin.
The final confirmation came in May 2016, when Theranos announced it had voided two years of results from its Edison device. A 2016 study in the Journal of Clinical Investigation found that Theranos results were flagged "outside their normal range" 1.6 times more often than other testing services, and that 68 percent of the lab measurements evaluated showed significant variability compared with other labs.
From Billionaire to Conviction: How Theranos Collapsed
At its peak in 2013 and 2014, Theranos was valued at $9 billion, and Holmes's stake was estimated at $4.5 billion — making Forbes name her the youngest self-made female billionaire in America. The company raised more than $700 million from investors including Rupert Murdoch, the Walton family, and Betsy DeVos, and it built an all-star board featuring Henry Kissinger, George Shultz, James Mattis, and William Perry.
The fall was swift once the technology's flaws were exposed. Walgreens and Safeway ended their partnerships. Forbes revised Holmes's net worth to zero in 2016. In 2018, the SEC charged Theranos, Holmes, and company president Sunny Balwani with fraud; Holmes settled, paying a $500,000 fine and accepting a 10-year ban from leading a public company. Theranos was dissolved in September 2018.
In January 2022, a jury convicted Holmes on four counts — three of wire fraud and one of conspiracy — for defrauding investors, while acquitting her on charges of defrauding patients. In November 2022, she was sentenced to 11-and-a-quarter years (135 months) in prison and ordered, jointly with Balwani, to pay $452 million in restitution. She reported to Federal Prison Camp Bryan in Texas on May 30, 2023.
Where Elizabeth Holmes Is Now — and the New Documentary
Holmes's appeal was rejected by the Ninth Circuit in February 2025. In December 2025, the Los Angeles Times reported she had begun campaigning for a presidential pardon, and she has separately asked the Trump administration to commute her sentence. In March 2026, the judge reduced her sentence by 12 months after reconsidering federal sentencing guidelines, bringing her term to about 10 years (123 months). With standard good-conduct credit, the Bureau of Prisons has projected she could be released around 2032.
Meanwhile, Holmes allowed cameras into her life in a way she never did before. The documentary "You Can See Everything," directed by Nathan Fielder and Lance Oppenheim and released by A24, follows Holmes and Billy Evans over roughly three years, beginning with the 34 days before she reported to prison. It premiered as a secret screening at the Telluride Film Festival in September 2026, drew strong early reviews, and includes time with actress Amanda Seyfried, who played Holmes in the Hulu series "The Dropout."
The Bottom Line: Key Points to Remember
- Theranos claimed its "Edison" and "miniLab" devices could run many tests from a single finger-prick drop of blood collected in a "nanotainer."
- Medical experts doubted the idea from the start, partly because a finger-prick sample is diluted by tissue fluid and too small to split across many tests reliably.
- Most Theranos tests were actually run on third-party machines, and the company later voided two years of Edison results.
- Holmes was convicted of defrauding investors in 2022 and is serving a reduced sentence of about 10 years at FPC Bryan, with a projected 2032 release.
- The 2026 A24 documentary "You Can See Everything," directed by Nathan Fielder and Lance Oppenheim, tells the story from inside Holmes's home in the weeks before she went to prison.
